ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.12
-0.04 (-0.57%)
Mar 5, 2026, 4:00 PM EST - Market closed
Company Description
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kristin Yarema |
Contact Details
Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States | |
| Phone | 858 345 6265 |
| Website | inmagenebio.com |
Stock Details
| Ticker Symbol | IMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G207 |
| ISIN Number | US45175G2075 |
| Employer ID | 81-1697316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristin Yarema Ph.D. | Chief Executive Officer, Director and Interim Principal Financial Officer |
| Dr. Kurinji Pandiyan Ph.D. | Chief Strategy and Operations Officer |
| Renuka Sivendran Ph.D. | Chief Technical Officer |
| Dr. Benjamin Porter-Brown M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Jan 6, 2026 | SCHEDULE 13G | Filing |
| Dec 18, 2025 | 424B3 | Prospectus |
| Dec 18, 2025 | 8-K | Current Report |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |